Overview
TRAW market data
Price History
TRAW price chart · 1M
- O
- 0.585000
- H
- 0.604400
- L
- 0.585000
- C
- 0.604400
- Vol
- 940.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.59
- Previous Close
- $0.53
- Day High
- $0.60
- Day Low
- $0.59
- 52 Week High
- $3.23
- 52 Week Low
- $0.45
- 7 Day Return
- +9.89%
- 30 Day Return
- +17.34%
- 90 Day Return
- -61.01%
- 1 Year Return
- -53.33%
- Daily Notional Volume
- $568.1 Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 0.96 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -616.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.43 – $3.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.8M · P/S 3.04.
Company News
HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price TargetBenzinga · Aug 18, 2026, 11:34 AM
Traws Pharma Q2 EPS $(0.16) Beats $(0.34) EstimateBenzinga · Aug 14, 2026, 8:56 PM
8-K filing — Traws Pharma, Inc. (TRAW)SEC EDGAR · Aug 14, 2026, 8:30 PM
WHO Director-General Ghebreyesus Says He Considers The Cruise Ship-Linked Hantavirus Outbreak To Be OverBenzinga · Jul 2, 2026, 1:25 PM
Traws PharmaFiles Prospectus For Mixed Shelf Offering Of Up To ~$139.2MBenzinga · Jul 1, 2026, 8:10 PM
Traws Pharma Announces That An Updated Toxicology Data Package Is Being Developed In Response To The UK MHRA's Information Requirements For Planned Testing Of Tivoxavir Marboxil In A Phase 2a Human Influenza Challenge StudyBenzinga · Jun 22, 2026, 11:15 AM
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For ThursdayBenzinga · Jun 18, 2026, 12:15 PM
HC Wainwright & Co. Downgrades Traws Pharma to Neutral, Announces $1 Price TargetBenzinga · Jun 18, 2026, 12:10 PM
Ladenburg Thalmann Downgrades Traws Pharma to NeutralBenzinga · Jun 15, 2026, 4:20 PM
Traws Pharma Stock Falls As UK Regulator Delays Key Flu StudyBenzinga · Jun 15, 2026, 3:15 PM